, Volume 179, Issue 5–6, pp 391–395 | Cite as

Detection and Quantification of Fluconazole Within Candida glabrata Biofilms

  • Célia F. Rodrigues
  • Sónia Silva
  • Joana Azeredo
  • Mariana HenriquesEmail author


Candida infections are often associated with biofilms and consequent high resistance to most common drugs (e.g. azoles). These resistance mechanisms are not only associated with the biofilm yeast physiology, but also with the presence of a diffusional barrier imposed by the biofilm matrix; however, the real biochemical role of the biofilm components remains very unclear. So, in order to further clarify this issue, we intend to determine, for the first time, fluconazole in biofilms within both supernatants and matrices. Candida biofilms were formed in the presence of fluconazole, and it was recovered from both supernatant and matrix cell-free fractions. Then, high-pressure liquid chromatography was used to identify and quantify the amount of drug that was present in the two fractions. Moreover, this study also showed that the presence of fluconazole in both fractions indicated that the drug administrated did not completely reach the cells, so this phenomena can easily be associated with lower biofilm susceptibility, since the drug administered did not completely reach the cells.


Candida Biofilm matrix Antifungal Method Resistance 



This work was supported by the Programa Operacional, Fatores de competitividade—COMPETE and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012, PEst-OE/EQB/LA0023/2013 and Célia F. Rodrigue’s SFRH/BD/93078/2013 PhD grant. The authors thank the Project “BioHealth—Biotechnology and Bioengineering approaches to improve health quality,” Ref. NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional do Norte (ON.2—O Novo Norte), QREN, FEDER. We also would like to acknowledge Pfizer®, S.A., for the kindly donation of fluconazole.

Conflict of interest

The authors declare no competing financial interest.


  1. 1.
    Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197–205.CrossRefPubMedGoogle Scholar
  2. 2.
    Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305.CrossRefPubMedGoogle Scholar
  3. 3.
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients. Surg Infect. 2003;4:263–71.CrossRefGoogle Scholar
  6. 6.
    Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2008;17:255–67.CrossRefGoogle Scholar
  7. 7.
    Samaranayake LP, Fidel PL, Naglik JR, et al. Fungal infections associated with HIV infection. Oral Dis. 2005;8:151–60.CrossRefGoogle Scholar
  8. 8.
    Rajendran R, Robertson DP, Hodge PJ, Lappin DF, Ramage G. Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. Mycopathologia. 2010;170:229–35.CrossRefPubMedGoogle Scholar
  9. 9.
    Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs. 2004;5:186–97.PubMedGoogle Scholar
  10. 10.
    Gerber F, Krummen M, Potgeter H, Roth A, Siffrin C, Spoendlin C. Practical aspects of fast reversed-phase high-performance liquid chromatography using 3 μm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. J Chromatogr A. 2004;1036(2):127–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Sadasivudu P, Shastri N, Sadanandam M. Development and validation Of RP-Hplc and UV methods of analysis for fluconazole in pharmaceutical solid dosage forms. Int J Chem Tech Res. 2009;1(4):1131–6.Google Scholar
  12. 12.
    Williams DW, Wilson MJ, Lewis MAO, Potts AJ. Identification of Candida species by PCR and restriction fragment length polymorphism analysis of intergenic spacer regions of ribosomal DNA. J Clin Microbiol. 1995;33:2476–9.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol. 2009;47:681–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014;33(5):673–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Prażyńska M, Gospodarek E. In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation. Mycopathologia. 2014;177(1-2):19–27.CrossRefPubMedGoogle Scholar
  16. 16.
    Nett JE. Future directions for anti-biofilm therapeutics targeting Candida. Expert Rev Anti Infect Ther. 2014;12(3):375–82.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Célia F. Rodrigues
    • 1
  • Sónia Silva
    • 1
  • Joana Azeredo
    • 1
  • Mariana Henriques
    • 1
    Email author
  1. 1.CEB, Centre of Biological Engineering, LIBRO – Laboratório de Investigação em Biofilmes Rosário OliveiraUniversity of MinhoBragaPortugal

Personalised recommendations